Nevisense
Save to shortlistLast reviewed Oct 31, 2026 against the sources listed on this page · How we review
At a glance
Nevisense is a point-of-care platform from SciBase that combines Electrical Impedance Spectroscopy (EIS) with AI ('augmented intelligence') to non-invasively assess atypical pigmented skin lesions…
- FDA:
- PMA P150046
- Epic:
- Not on record
- Named users:
- 1 named in public reports
- Published study:
- Not on record
Description
Nevisense is a point-of-care platform from SciBase that combines Electrical Impedance Spectroscopy (EIS) with AI ('augmented intelligence') to non-invasively assess atypical pigmented skin lesions for melanoma and other skin cancers. It passes a low-voltage current through tissue at 35 frequencies and outputs a 0-10 risk score to help dermatologists decide whether to biopsy or monitor a lesion. It is the only FDA-approved device for melanoma detection in the United States and holds European MDR approval.
Quick answers
Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review
- Is Nevisense FDA cleared?
- The public FDA database has one record that our team matched to Nevisense. The most recent is PMA P150046 (Nevisense), decided Jun 2017. Check that the cleared use matches how you plan to use it.FDA record P150046
- Which health systems use Nevisense?
- Linked public reports name one organization: SCARS Center. "Who's using this" below lists them all, plus any the maker reports. Ask the vendor for a reference at an organization like yours.SCARS Center (Medical Device Network)
Security & contracting
The maker has not reported these details yet. Ask the vendor directly during evaluation.
- Workflow stage
- Not reported
- Integrations
- Not reported
- Data inputs
- Not reported
- Deployment
- Not reported
- Signs a BAA
- Not reported
- SOC 2 report
- Not reported
- HITRUST
- Not reported
- Evidence type
- Not assessed
Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.
Who's using this
3 organizationsOrganizations named in public announcements or by the developer. Inclusion is not an endorsement.
Reported by the developer
Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.
Get weekly updates for Dermatology
Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.
Sources
This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.
WebsiteFDA database records
- P150046 · PMA · Jun 2017Nevisense
Matched by our team from the public FDA database; checked Nov 10, 2026.
History (3)Show
Dated events on this listing's public record, newest first.
Developer
SciBase AB
SciBase AB (Stockholm/Sundbyberg, Sweden)
Evaluating this tool?
Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.
Prepare evaluation packetChecklist for your role: Admin · Physician · IT · Compliance
Compare similar tools →